2023
Prevalence of HIV-1 infection and associated characteristics in a Brazilian indigenous population: a cross-sectional study
Schnaufer E, Barbosa M, Marques M, Brito G, Ferreira T, Ribeiro A, Valiente A, Machado I, Gonçalves C, Tanaka T, Guimarães M, Ribeiro S, Croda J, Simionatto S. Prevalence of HIV-1 infection and associated characteristics in a Brazilian indigenous population: a cross-sectional study. The Lancet Regional Health - Americas 2023, 25: 100562. PMID: 37559945, PMCID: PMC10407292, DOI: 10.1016/j.lana.2023.100562.Peer-Reviewed Original ResearchDrug resistance mutationsHIV-1 infectionReverse transcriptase inhibitorCross-sectional studyViral loadHIV infectionTranscriptase inhibitorHIV-1HIV-1 drug resistance mutationsHIV-1 viral loadNon-nucleoside reverse transcriptase inhibitorNucleoside reverse transcriptase inhibitorHIV-1 subtype CT-lymphocyte countsVulnerable populationsWeeks of treatmentCopies/mLHigh viral loadHealth promotion strategiesTime of recruitmentOngoing molecular surveillanceAreas of preventionAntiretroviral therapyHIV seroprevalenceLymphocyte countHSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal
Pierce C, Loh L, Steach H, Cheshenko N, Preston-Hurlburt P, Zhang F, Stransky S, Kravets L, Sidoli S, Philbrick W, Nassar M, Krishnaswamy S, Herold K, Herold B. HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal. Journal Of Clinical Investigation 2023, 133: e164317. PMID: 37079384, PMCID: PMC10232005, DOI: 10.1172/jci164317.Peer-Reviewed Original ResearchConceptsHIV-1 reactivationHIV latency reversalT cellsLatency reversalHuman CD4HIV-1 viral loadHIV-1 restriction factorsHSV-2 recurrencesHSV-2 infectionHIV-1 latencyUpregulation of MALAT1Primary human CD4HSV-2 proteinsViral loadHIV replicationPeripheral bloodMALAT1 expressionHSV-2Tissue reservoirsCD4Viral replicationExpression of transcriptsBystander cellsRestriction factorsMALAT1
2019
661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
Emu B, DeJesus E, Berhe M, Leider J, Creticos C, Weinheimer S, Cohen Z. 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311). Open Forum Infectious Diseases 2019, 6: s303-s303. PMCID: PMC6811265, DOI: 10.1093/ofid/ofz360.729.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsWeeks of treatmentCopies/mLViral loadCopies/Cohort 2Multidrug-resistant HIV-1 infectionDay 0HIV-1 RNA levelsImmune reconstitution inflammatory syndromeLog10 copies/mLHIV-1 viral loadPivotal phase 3 studiesCohort 2 patientsDurable viral suppressionMajor eligibility criteriaReconstitution inflammatory syndromeWeek 24 visitCD4 cell countMedian viral loadTreatment-experienced patientsCells/mm3Phase 3 studyInjection site reactionsLog10 copies/
2018
Treatment Outcomes of Brazilian Inmates with Treponema pallidum and Human Immunodeficiency Virus Infection: A Prospective Cohort Study.
Bet G, Souza G, Croda J, Correa M, de Sales R, Santos R, Viebrantz Enne Sgarbi R, Yassuda R, Coimbra Motta-Castro A, Pompílio M, Simionatto S. Treatment Outcomes of Brazilian Inmates with Treponema pallidum and Human Immunodeficiency Virus Infection: A Prospective Cohort Study. American Journal Of Tropical Medicine And Hygiene 2018, 98: 1603-1608. PMID: 29737273, PMCID: PMC6086195, DOI: 10.4269/ajtmh.17-0592.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV-1 viral loadProspective cohort studyPoor treatment outcomesTreatment outcomesCohort studyHIV infectionViral loadHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionCopies/mLMedical record dataPublic health programsSyphilis treatmentImmunodeficiency virusAcquired syphilisRisk factorsSerological testingVirus infectionBlood samplesMultivariate analysisHealth programsNew casesInfectionTreponema pallidum
2010
Effect of treating co-infections on HIV-1 viral load: a systematic review
Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. The Lancet Infectious Diseases 2010, 10: 455-463. PMID: 20610327, PMCID: PMC3071714, DOI: 10.1016/s1473-3099(10)70093-1.Peer-Reviewed Original ResearchConceptsViral load differencesViral loadPlasma HIV-1 RNA concentrationSystematic reviewMean plasma viral loadPlasma HIV RNA concentrationHIV-1 RNA concentrationsHIV-1 viral loadHIV RNA concentrationPlasma viral loadHIV transmission riskViral load reductionNon-pathogenic infectionsCo-infecting pathogensSyphilis treatmentHIV progressionTuberculosis treatmentEligible studiesPopulation-level benefitsTransmission riskLow-income countriesHIVTreatmentInfectionReview
2008
Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa
Mosam A, Hurkchand H, Cassol E, Page T, Cassol S, Bodasing U, Aboobaker J, Dawood H, Friedland G, Coovadia H. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. International Journal Of STD & AIDS 2008, 19: 400-405. PMID: 18595878, DOI: 10.1258/ijsa.2008.007301.Peer-Reviewed Original ResearchConceptsHIV-1-associated Kaposi's sarcomaKaposi's sarcomaCD4/CD8 cell countsHIV-1 viral loadCD8 cell countsCutaneous Kaposi's sarcomaPoor disease prognosisVirological featuresViral loadClinical parametersPatients 99Male ratioSevere diseaseDisease prognosisCell countSarcomaHIVDescriptive studyAfrican settingEqual femalePatientsOne-thirdDiseaseFemalesWomen
2002
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne J, Collaboration T. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet 2002, 360: 119-129. PMID: 12126821, DOI: 10.1016/s0140-6736(02)09411-4.Peer-Reviewed Original ResearchConceptsCells/microLCD4 cell countBaseline CD4 cell countActive antiretroviral therapyProbability of progressionCell countAntiretroviral therapyCohort studyBaseline HIV-1 viral loadCD4 cells/microLCD4 cells/microL.HIV-1 viral loadHIV-1-infected patientsART Cohort CollaborationTreatment-naive patientsCells/microL.Dominant prognostic factorFuture treatment guidelinesInjection drug useHigh-risk stratumLow-risk stratumSingle cohort studyCohort CollaborationNew AIDSAdult patients
1999
Comparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load
Rompalo A, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg S, Warren D, Farzadegan H, Vlahov D, Smith D. Comparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 448-454. PMID: 10225226, DOI: 10.1097/00042560-199904150-00006.Peer-Reviewed Original ResearchConceptsHIV-1 viral loadPlasma viral loadBody mass indexHIV-1 plasma viral loadOral hairy leukoplakiaInjection drug useViral loadInjection drug usersRisk groupsHIV infectionCell countDrug useHairy leukoplakiaCells/Clinical manifestationsHeterosexual contactMedian HIV-1 viral loadPlasma HIV-1 viral loadUndetectable HIV-1 viral loadPlasma viral load levelsHIV viral loadIntravenous drug useViral load levelsPopulation of HIVPrevalence of HIVRelationship between HIV‐1 viral load and continued drug use in untreated infected injection drug users
CARRIERI M, TAMALET C, VLAHOV D, YAHI N, CHESNEY M, MOATTI J. Relationship between HIV‐1 viral load and continued drug use in untreated infected injection drug users. Addiction Biology 1999, 4: 197-202. PMID: 20575786, DOI: 10.1080/13556219971704.Peer-Reviewed Original ResearchRecent heroin injectionViral loadDrug useHeroin injectionHIV-1 plasma viral loadInfected injection drug usersHIV-1 viral loadHIV viral loadPlasma viral loadDevelopment of AIDSContinued drug useInjection drug usersLong-term progressionSelf-administered questionnaireAntiretroviral treatmentClinical stageClinical examinationMedical recordsOutpatient carePatientsDrug usersSerological assaysHospital departmentsLaboratory informationRisk practicesCell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men
Lyles C, Graham N, Astemborski J, Vlahov D, Margolick J, Saah A, Farzadegan H. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. European Journal Of Epidemiology 1999, 15: 99-108. PMID: 10204638, DOI: 10.1023/a:1007556327269.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionFemaleFollow-Up StudiesHIV InfectionsHIV-1Homosexuality, MaleHumansImmunocompromised HostLeukocytes, MononuclearMalePredictive Value of TestsProportional Hazards ModelsRisk FactorsSubstance Abuse, IntravenousSurvival AnalysisSurvival RateViral LoadViremiaConceptsHIV-1 viral loadViral loadHomosexual menRisk groupsHIV-1Relative hazardDrug usersPeripheral blood mononuclear cellsMicroculture techniqueBlood mononuclear cellsInjection drug usersHIV-1 progressionInitial CD4Clinical progressionMononuclear cellsNegative culturesPredictive valueSurvival analysisBacterial infectionsTotal participantsAIDSProgressionInfectious unitsCells/Death
1998
Sex differences in HIV-1 viral load and progression to AIDS
Farzadegan H, Hoover D, Astemborski J, Lyles C, Margolick J, Markham R, Quinn T, Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1998, 352: 1510-1514. PMID: 9820299, DOI: 10.1016/s0140-6736(98)02372-1.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell countProportional hazards modelBranched-chain DNAViral loadQuantitative microcultureReverse transcriptase-PCRPlasma HIV-1 RNA measurementsCell countHIV-1 RNA measurementsUnivariate proportional hazard modelHIV-1 viral loadSame viral loadViral load associationsVisit 3 yearsHIV-1 loadViral load measurementsAntiretroviral therapyAntiretroviral treatmentBaseline visitCommunity clinicsObservational studyHIV-1Current recommendationsHigh riskPrognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett J, Margolick J, Lyles C, Nelson K, Smith D, Holmberg S, Farzadegan H. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count. JAMA 1998, 279: 35-40. PMID: 9424041, DOI: 10.1001/jama.279.1.35.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBiomarkersBlack or African AmericanCD4 Lymphocyte CountDisease ProgressionFemaleHIV-1HumansMalePrognosisProportional Hazards ModelsProspective StudiesRegression AnalysisRNA, ViralSubstance Abuse, IntravenousSurvival AnalysisViral LoadConceptsInfectious disease deathsInjection drug usersPlasma viral loadViral loadDisease deathsCell countDrug usersPrognostic indicatorHuman immunodeficiency virus type 1 (HIV-1) viral loadAfrican American injection drug usersPlasma HIV-1 RNAHIV-1 viral loadInfectious diseasesClinical AIDS diagnosisLevels of CD4Kaplan-Meier analysisHIV-1 RNAPrognosis of personsPowerful prognostic informationProportional hazards modelCases of AIDSGood predictive valueCell count measurementsMedian followCohort study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply